MiMedx Group (NASDAQ:MDXG) Stock Price Up 0.7% – What’s Next?

MiMedx Group, Inc (NASDAQ:MDXG)’s share price traded up 0.7% during trading on Monday . The company traded as high as $4.35 and last traded at $4.33. Approximately 737,038 shares were traded during mid-day trading, a decline of 40% from the average session volume of 1,228,400 shares. The stock had previously closed at $4.30.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Citizens Jmp lowered their target price on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a research report on Thursday, April 30th. Wall Street Zen downgraded shares of MiMedx Group from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Craig Hallum decreased their price target on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Finally, Weiss Ratings downgraded shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

MiMedx Group Trading Down 3.5%

The company has a quick ratio of 4.81, a current ratio of 5.39 and a debt-to-equity ratio of 0.07. The firm has a 50 day moving average price of $3.83 and a 200 day moving average price of $4.35. The stock has a market capitalization of $621.10 million, a PE ratio of 20.85 and a beta of 1.45.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, April 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. The company had revenue of $58.99 million for the quarter, compared to analysts’ expectations of $65.80 million. MiMedx Group had a return on equity of 21.03% and a net margin of 7.88%. Equities analysts expect that MiMedx Group, Inc will post -0.09 EPS for the current fiscal year.

Institutional Trading of MiMedx Group

Institutional investors and hedge funds have recently made changes to their positions in the company. Nantahala Capital Management LLC purchased a new position in MiMedx Group during the third quarter worth about $10,237,000. Marshall Wace LLP increased its stake in MiMedx Group by 864.9% in the 4th quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock valued at $9,351,000 after buying an additional 1,238,132 shares during the last quarter. Hillsdale Investment Management Inc. bought a new position in shares of MiMedx Group during the 4th quarter worth approximately $7,134,000. Disciplined Growth Investors Inc. MN boosted its stake in shares of MiMedx Group by 283.0% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company’s stock worth $9,656,000 after buying an additional 1,022,202 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY boosted its stake in shares of MiMedx Group by 39.1% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 3,410,300 shares of the company’s stock worth $13,471,000 after buying an additional 959,100 shares during the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.